CA2960279A1 - Isoxazole carboxamides as irreversible smyd inhibitors - Google Patents

Isoxazole carboxamides as irreversible smyd inhibitors Download PDF

Info

Publication number
CA2960279A1
CA2960279A1 CA2960279A CA2960279A CA2960279A1 CA 2960279 A1 CA2960279 A1 CA 2960279A1 CA 2960279 A CA2960279 A CA 2960279A CA 2960279 A CA2960279 A CA 2960279A CA 2960279 A1 CA2960279 A1 CA 2960279A1
Authority
CA
Canada
Prior art keywords
cancer
cell
tumor
carcinoma
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2960279A
Other languages
English (en)
French (fr)
Inventor
Richard Chesworth
Megan Alene Cloonan FOLEY
Kevin Wayne Kuntz
Lorna Helen Mitchell
Russell C. Petter
Carl Eric SCHWARTZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epizyme Inc
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of CA2960279A1 publication Critical patent/CA2960279A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA2960279A 2014-09-10 2015-09-09 Isoxazole carboxamides as irreversible smyd inhibitors Abandoned CA2960279A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048760P 2014-09-10 2014-09-10
US62/048,760 2014-09-10
PCT/US2015/049231 WO2016040511A1 (en) 2014-09-10 2015-09-09 Isoxazole carboxamides as irreversible smyd inhibitors

Publications (1)

Publication Number Publication Date
CA2960279A1 true CA2960279A1 (en) 2016-03-17

Family

ID=55459533

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2960279A Abandoned CA2960279A1 (en) 2014-09-10 2015-09-09 Isoxazole carboxamides as irreversible smyd inhibitors

Country Status (6)

Country Link
US (2) US10179773B2 (enExample)
EP (1) EP3193606B1 (enExample)
JP (1) JP2017528460A (enExample)
AU (1) AU2015315180A1 (enExample)
CA (1) CA2960279A1 (enExample)
WO (1) WO2016040511A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017004589A2 (pt) 2014-09-10 2018-01-23 Epizyme Inc composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
AU2015315174B2 (en) 2014-09-10 2019-12-12 Epizyme, Inc. Smyd inhibitors
WO2016040511A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
EP3190891B1 (en) 2014-09-10 2020-01-15 Epizyme, Inc. Isoxazolecarboxamide substituted by a cyclohexylamine as smyd protein inhibitors
CA2960274A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamide compounds
CN114246851B (zh) * 2021-11-09 2024-01-26 澳门科技大学 一种组蛋白甲基转移酶smyd3小分子抑制剂的合成方法及用途
CN115998869B (zh) * 2022-09-23 2025-08-05 华中科技大学同济医学院附属同济医院 组蛋白甲基转移酶smyd2在制备防治血管损伤后内膜新生导致再狭窄的药物中的应用
IT202200021138A1 (it) * 2022-10-13 2024-04-13 Istituto Di Ricovero E Cura A Carattere Scient Saverio De Bellis Formulati farmaceutici con attività inibente le metiltrasferasi istoniche per il trattamento di patologie neoplastiche
CN116211867A (zh) * 2022-12-30 2023-06-06 复旦大学附属肿瘤医院 Az505和恩杂鲁胺在制备治疗前列腺癌药物中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006518368A (ja) * 2003-02-21 2006-08-10 ファイザー・インク プロテインキナーゼ阻害剤としてのｎ−ヘテロシクリル置換アミノチアゾール誘導体
CN1528745A (zh) * 2003-10-21 2004-09-15 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其制备方法
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
WO2008137834A2 (en) 2007-05-04 2008-11-13 Osi Pharmaceuticals, Inc. Crystal structure of smyd3 protein
WO2013043826A1 (en) * 2011-09-21 2013-03-28 Abbvie Inc. Tricyclic compounds useful as protein kinase inhibitors
EP3193609A4 (en) 2014-09-10 2018-02-28 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
BR112017004589A2 (pt) 2014-09-10 2018-01-23 Epizyme Inc composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
AU2015315174B2 (en) 2014-09-10 2019-12-12 Epizyme, Inc. Smyd inhibitors
JP2017527577A (ja) 2014-09-10 2017-09-21 エピザイム，インコーポレイティド 置換ピロリジン化合物
WO2016040511A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
EP3190891B1 (en) 2014-09-10 2020-01-15 Epizyme, Inc. Isoxazolecarboxamide substituted by a cyclohexylamine as smyd protein inhibitors
CA2960274A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamide compounds

Also Published As

Publication number Publication date
US20190241529A1 (en) 2019-08-08
US10179773B2 (en) 2019-01-15
EP3193606B1 (en) 2020-06-24
US10669243B2 (en) 2020-06-02
EP3193606A1 (en) 2017-07-26
EP3193606A4 (en) 2018-04-11
WO2016040511A1 (en) 2016-03-17
AU2015315180A1 (en) 2017-03-16
US20180230110A1 (en) 2018-08-16
JP2017528460A (ja) 2017-09-28

Similar Documents

Publication Publication Date Title
US10669243B2 (en) Isoxazole carboxamides as irreversible SMYD inhibitors
AU2025204601A1 (en) Substituted indoles and methods of use thereof
US10266526B2 (en) Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer
EP3193604B1 (en) Substituted n-(pyrrolidin-3-yl)isoxazole-3-carboxamide compounds
US10577363B2 (en) Substituted piperidine compounds
US10428029B2 (en) Isoxazole carboxamide compounds
US20200048195A1 (en) Substituted pyrrolidine carboxamide compounds
JP2022523073A (ja) 化合物及びその使用
EP3190891B1 (en) Isoxazolecarboxamide substituted by a cyclohexylamine as smyd protein inhibitors
US20200123142A1 (en) Substituted Cyclohexylamine Compounds

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211201